SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc is trending as investors monitor its push toward the $30 resistance level, fueled by enthusiasm for its expanding GLP-1 and peptide growth strategy. The community is heavily focused on persistent relative strength, potential short squeeze mechanics due to high short interest, and the company's ability to capitalize on the growing global demand for weight-management solutions.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending following the abrupt departure of CEO Mike Lyons and the immediate appointment of Takis Georgakopoulos, a transition that has triggered significant volatility and investor concern over the company's growth outlook. While some market participants view the leadership change as a necessary reset and a potential long-term value play, the community remains divided, with active discussions focused on the companys recent earnings performance, industry-wide fintech valuation pressures, and the potential for activist intervention.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is seeing intense community debate following news that Fox is acquiring the company in a $22 billion cash-and-stock deal. While some investors are skeptical about the valuation and the long-term implications of the deal structure, others are focused on the potential for a bidding war or questioning how the acquisition will integrate into the broader streaming and advertising landscape.

BTQ Technologies Corp. engages in the business of post-quantum encryption. Its products include: QCIM, QSSN, OSS, QPoW, QRiNG. The company was founded by Nicolas Roussy Newton on Novemeber 23, 1983 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ is experiencing heightened interest as investors weigh its potential as a quantum cybersecurity play against skepticism regarding its lack of commercial product and revenue. Community discussions are driven by speculation over a possible buyout or catalyst-driven breakout, while some traders closely monitor technical indicators and institutional ownership for signs of a turnaround.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is experiencing significant bullish sentiment as Bank of America and Morgan Stanley recently initiated or raised price targets on the stock, reflecting strong institutional conviction in its pivot from legacy mining to high-performance computing infrastructure. The community is actively discussing the stock's role in the broader AI compute expansion, focusing on upcoming catalysts like potential site developments in Kentucky and the company's long-term competitive positioning in power-heavy data center markets.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors debate the impact of potential Middle Eastern peace negotiations on its stock price, with many community members viewing recent price dips as accumulation opportunities due to the company's strong long-term LNG fundamentals. While short-term volatility is driven by geopolitical headlines and insider selling, supporters remain focused on the firm's expanding export capacity and its role in supplying energy-hungry data centers.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense volatility as the community debates whether the recent price decline is a shakeout opportunity or a fundamental breakdown. Investors are heavily focused on the company's 10x capacity expansion and high cash reserves, while the community remains divided between bullish sentiment regarding AI infrastructure demand and bearish concerns over management communication and ongoing class-action litigation.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class A

Fox Corporation

Fox Corporation is trending as investors digest the strategic implications of the company's $22 billion acquisition of Roku, sparking intense debate regarding the deal's valuation, potential dilution, and long-term positioning in the competitive streaming and connected-TV advertising markets. While some members of the community express frustration over the company's recent stock performance and content accessibility issues, others see the move as a bold, albeit expensive, bet on digital transformation and ad-tech leverage.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum is gaining attention as a potential 'Microsoft of the quantum computing world' due to its specialized software focus and strategic backing from industry heavyweights like IonQ and Dell. Investors are particularly focused on the stock's ultra-low float and quiet accumulation phase, with many viewing it as a significant, under-the-radar opportunity within the broader quantum sector rotation.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently a focal point as investors navigate heightened geopolitical instability and uncertainty regarding the potential resolution of conflicts in the Middle East, which continues to impact energy prices and Treasury yields. The market is actively debating the stability of the bond market in relation to evolving interest rate expectations, while participants closely monitor institutional positioning for signs of either a significant reversal or continued defensive rotation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics 

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +29.58% and +193.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +3.47% and +8.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-cytomx-therapeutics-inc-stock...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Analysts

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and nine have assigned...

Wall Street Zen Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong Sell

Wall Street Zen lowered shares of CytomX Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday...

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving Average - Here's What Happened

CytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below 50-Day Moving Average - What's Next...

Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock traders acquired 13,090 put options on the company. This...

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 6.3%  - Time to Buy?

CytomX Therapeutics (NASDAQ:CTMX) Trading Up 6.3% - What's Next...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat Ratings...

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.08	--	--	N/A
Q1 '26	-$0.12	-$0.10	17.42%	BEAT
Q4 '25	-$0.09	-$0.17	-85.33%	MISSED
Q3 '25	-$0.05	-$0.09	-82.50%	MISSED
Q2 '25	-$0.06	$0.00	100.00%	BEAT

CTMXCytomX Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CTMX News